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Purpose: The goal of this study was to assess the
long-term safety and efficacy of mepolizumab in
patients with the most severe eosinophilic asthma.
Methods: This multicenter, open-label, long-term,
Phase IIIb study (COSMEX [COSMOS Extension];
201312/NCT02135692) enrolled patients from the
52-week, open-label extension study COSMOS (A
Study to Determine Long-term Safety of
Mepolizumab in Asthmatic Subjects) that previously
enrolled patients from the double-blinded, placebo-
controlled Phase III studies MENSA (Mepolizumab
as Adjunctive Therapy in Patients with Severe15 Current address: Avillion US Inc., Northbrook, IL,
USA.
October 2019Asthma) and SIRIUS (Steroid Reduction with
Mepolizumab Study). To enter COSMEX, patients
had to have life-threatening/seriously debilitating
asthma before entering MENSA or SIRIUS and to
have completed these previous studies with
demonstrated improvement while receiving
mepolizumab. In COSMEX, patients received
mepolizumab 100 mg subcutaneously every 4 weeks
as add-on therapy for up to 172 weeks. Primary
endpoints were adverse event frequency and
exacerbation rate per year; also assessed were forcedhttps://doi.org/10.1016/j.clinthera.2019.07.007
0149-2918/$ - see front matter
© 2019 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Clinical Therapeuticsexpiratory volume in 1 s, Asthma Control
Questionnaire-5 score, and daily oral corticosteroid
(OCS) use.
Findings: Of the 340 patients enrolled, 339 received
mepolizumab; median treatment duration within this
extension study was 2.2 years, equating to 718
patient-years of additional exposure. No new safety
signals were identified. Patients receiving
mepolizumab throughout this study and previous
studies had lasting reductions in exacerbation rate
and daily OCS use and improvements in forced
expiratory volume in 1 s and Asthma Control
Questionnaire-5 score. In COSMEX, the on-
treatment exacerbation rate (95% CI) was 0.93
(0.81e1.06) event/year for clinically significant
exacerbations, 0.13 (0.10e0.18) event/year for
exacerbations requiring hospitalization/emergency
department visit, and 0.07 (0.05e0.10) event/year for
exacerbations requiring hospitalization. In patients
requiring systemic/oral corticosteroids with 128
weeks of continuous enrollment across SIRIUS,
COSMOS, and COSMEX, mepolizumab maintained
the median daily OCS dose at 1.3e2.8 mg during
COSMEX, with additional patients no longer
requiring OCS after extended mepolizumab treatment.
Implications: This study indicates that long-term
mepolizumab treatment is well tolerated and
associated with sustained clinical benefits in patients
with severe eosinophilic asthma. ClinicalTrials.gov
identifier: NCT02135692. (Clin Ther.
2019;41:2041e2056) © 2019 The Authors. Pub-
lished by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Key Words: asthma exacerbations, corticosteroids,
long-term safety, mepolizumab, severe eosinophilic
asthma.INTRODUCTION
Asthma is a common, heterogeneous disease
characterized by chronic airway inflammation,
affecting an estimated 358 million people
worldwide.1e3 Patients with severe, persistent asthma
comprise ~5%e10% of the total asthma population
and represent a considerable health care burden as
they have increased morbidity and mortality,
frequently require hospitalization, and have high2042treatment costs.4 There are several clinically
recognized phenotypes of severe asthma, including
severe eosinophilic asthma, which is characterized by
elevated levels of peripheral eosinophils and frequent
exacerbations.5
Mepolizumab, indicated for patients with severe
eosinophilic asthma, is a humanized monoclonal
antibody against interleukin-5.6,7 It selectively inhibits
eosinophilic inflammation8,9 and reduces eosinophil
levels in sputum and blood.10 The safety and efficacy
of mepolizumab have been investigated in several
Phase III clinical trials. The MENSA (Mepolizumab
as Adjunctive Therapy in Patients with Severe
Asthma; NCT01691521) trial assessed the efficacy of
subcutaneous (SC) and intravenous (IV) mepolizumab
in patients with recurrent asthma exacerbations and
evidence of eosinophilic inflammation despite high-
dose inhaled corticosteroids (ICS). Mepolizumab
significantly reduced asthma exacerbations by 53%
(SC) and 47% (IV), and improved quality of life and
asthma control, compared with placebo.11 In the
SIRIUS (Steroid Reduction with Mepolizumab Study;
NCT01691508) trial, SC administration of
mepolizumab resulted in a significant corticosteroid-
sparing effect, reduced exacerbations by 32%, and
improved control of asthma symptoms and quality of
life compared with placebo in patients with severe
eosinophilic asthma who required daily oral
corticosteroid (OCS) therapy to maintain asthma
control.12 Findings from both studies also indicated
that mepolizumab has a favorable safety profile.11,12
The long-term safety and efficacy of mepolizumab
SC treatment in patients with severe eosinophilic
asthma were also assessed in the COSMOS open-
label extension study (NCT01842607).13 This 52-
week open-label extension study enrolled patients
from the double-blind, placebo-controlled MENSA
and SIRIUS studies, and showed that mepolizumab
has a durable and stable response over an 18-month
continuous treatment period, with reductions in
exacerbation rate and OCS dosing maintained
throughout the COSMOS study period.
Given the considerable burden of severe eosinophilic
asthma, both in terms of health care costs and health-
related quality of life, it is important to identify suitable
and predictable management approaches for patients.
The aim of the current study, COSMEX (COSMOS
Extension), was to extend the findings of the
MENSA, SIRIUS, and COSMOS studies. WeVolume 41 Number 10
S. Khurana et al.investigated the long-term safety and clinical efficacy of
mepolizumab in a subset of patients with the most
severe forms of severe eosinophilic asthma who had
previously displayed improved disease control while
receiving mepolizumab as add-on therapy.PATIENTS AND METHODS
Study Design
COSMEX (201312/NCT02135692) was a
multicenter, open-label, long-term, Phase IIIb study of
mepolizumab in a subset of patients with the most
severe forms of severe eosinophilic asthma
(specifically a history of life-threatening or seriously
debilitating asthma; definitions are given in the
following section and in Table I). The study was
conducted at 116 centers in 18 countries (see the





Definitions for COSMEX Study
Life-threatening
asthma
At least 1 of:
 History of 1 intubation during t
lifetime
 1 Hospitalization for asth
exacerbation within the 12 mo befo
MENSA or SIRIUS screening
 3 Exacerbations in the 12 mo be
screening in MENSA
 An optimized OCS dose (prednis




 Percent-predicted FEV1 of 50%
randomization for MENSA or SIRIU
 And either an ACQ-5 score 3
SGRQ total score 60 at MENSA
SIRIUS randomization
ACQ-5 ¼ Asthma Control Questionnaire-5; COSMOS ¼ A Study t
Subjects; FEV1 ¼ forced expiratory volume in 1 s; ICS ¼ inhaled
George's Respiratory Questionnaire.
* Patients were required to meet the definition of having life-threa
health status of each patient before MENSA (Mepolizumab as Ad
(Steroid Reduction with Mepolizumab Study).
October 2019doi:10.1016/j.clinthera.2019.07.007) between May
29, 2014, and October 5, 2017, and completed after
all patients met a protocol-defined discontinuation
criterion. Mepolizumab 100 mg SC was administered
approximately every 4 weeks for up to 172 weeks.
Patients continued to receive standard-of-care asthma
therapy for the duration of the study, which could be
adjusted at the physicians’ discretion. After study
completion, patients could enter another
mepolizumab study (201810/NCT02555371 or
201956/NCT02543112) or receive mepolizumab
commercially outside of a clinical trial, if locally
available.
The study was approved by the appropriate
regulatory and ethics committees and was performed
in accordance with the Declaration of Helsinki 2008
and Good Clinical Practice guideline. WrittenSMOS Extension).







 Must have been receiving ICS controller
medication (fluticasone propionate 500 mg/
d or equivalent) for the previous 8 mo
 And must have previously demonstrated a
protocol-defined clinical benefit (see the
Supplemental Material in the online version at
doi:10.1016/j.clinthera.2019.07.007) from






o Determine Long-term Safety of Mepolizumab in Asthmatic
corticosteroids; OCS ¼ oral corticosteroids; SGRQ ¼ St.
tening asthma or seriously debilitating asthma based on the
junctive Therapy in Patients with Severe Asthma) or SIRIUS
2043
Clinical Therapeuticsinformed consent was obtained from each patient
before study participation.
Patients
Patients with the most severe forms of severe
eosinophilic asthma (eg, a history of life-threatening
or seriously debilitating asthma) were enrolled from
the COSMOS study (MEA115661/NCT01842607).13
Before COSMOS, patients had completed either
MENSA (MEA115588/NCT01691521)11 or SIRIUS
(MEA115575/NCT01691508)12 (Figure 1). For the
MENSA and SIRIUS studies, patients had severe
eosinophilic asthma and required high-dose ICS with
additional controller(s) and a blood eosinophil level
150 cells/mL at the initiation of treatment or
300 cells/mL during the year before study start.
Regarding COSMEX entry eligibility, patients must
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Figure 1. Duration and patient contribution to the COS
MEX mepolizumab-responsive patient popula
SIRIUS (Steroid Reduction with Mepolizumab S
(Mepolizumab as Adjunctive Therapy in Patien
from SIRIUS were enrolled, and 46% (266 of 57
follow-up period after COSMOS (A Study to D
matic Subjects) was not required for patients e
of COSMEX, patients could enter a further m
mepolizumab commercially outside of a clinical
(see the Supplemental Material in the onlin
IV ¼ intravenous; SC ¼ subcutaneous.
2044(fluticasone propionate 500 mg/d or equivalent) for
the previous 8 months and must have previously
reported a protocol-defined clinical benefit (see the
Supplemental Material in the online version at doi:10.
1016/j.clinthera.2019.07.007) from mepolizumab
within the MENSA, SIRIUS, or COSMOS studies.
When identifying the most severe forms of severe
eosinophilic asthma for COSMEX, “life-threatening”
asthma was defined as history of 1 intubation
during the patient's lifetime, 1 hospitalization for
asthma exacerbation within the 12 months before
MENSA or SIRIUS screening, and 3 exacerbations
in the 12 months before MENSA screening or an
optimized OCS dose (prednisone equivalent)
10 mg at SIRIUS randomization. “Seriously
debilitating” asthma was defined as percent-predicted
forced expiratory volume in 1 s (FEV1) 50% and
either an Asthma Control Questionnaire-5 (ACQ-5)172
Duration in weeks
COSMEX (N = 339* )
Mepolizumab 100 mg SC




MEX (COSMOS Extension) study. Overall, the COS-
tion comprised 22% (73 of 339) of patients from
tudy) and 78% (266 of 339) of patients from MENSA
ts with Severe Asthma); 54% (73 of 135) of patients
6) of patients from MENSA were enrolled. The safety
etermine Long-term Safety of Mepolizumab in Asth-
nrolling immediately into COSMEX. After completion
epolizumab study (201810 or 201956) or receive
trial, if locally available. *One patient failed screening
e version at doi:10.1016/j.clinthera.2019.07.007).
Volume 41 Number 10
S. Khurana et al.score 3 or St. George's Respiratory Questionnaire
total score 60 at MENSA or SIRIUS
randomization. Exclusion criteria are listed in the
Supplemental Material in the online version at
doi:10.1016/j.clinthera.2019.07.007.
There was a treatment gap of varying length
between COSMOS and COSMEX. Because the effect
of mepolizumab wanes ~3 months after stopping
treatment (leading to a rise in eosinophil levels),
patients were stratified into 2 groups for analysis:
those with a treatment interval 12 weeks
(continuous therapy group) or >12 weeks
(interrupted therapy group) between COSMOS and
COSMEX.
Endpoints
The primary safety endpoint was the frequency of
adverse events (AEs), serious AEs (SAEs), and AEs of
special interest (see the Supplemental Material in the
online version at doi:10.1016/j.clinthera.2019.07.
007). Deaths from any cause and selected
cardiovascular events were adjudicated by a Clinical
Endpoint Committee. Secondary safety endpoints
included the number of withdrawals due to AEs or
lack of efficacy, and the frequency of positive
antiemepolizumab-binding antibodies and of
neutralizing antibodies. A tiered testing approach was
used for immunogenicity analyses, which involved
screening and confirmation of antidrug antibodies
(using a binding antibody assay), followed by
titration and analysis of neutralizing antibodies (using
an indirect ligand-binding assay). Samples were
diluted with an antieinterleukin-5 blocking antibody
and incubated with biotin and ruthenium drug
conjugates; a screening cut-point was used, which
was statistically calculated to achieve a 5% false-
positive response rate. Positive antidrug antibody
samples were confirmed by repeating the analyses in
the presence of excess drug; a 1% false-positive rate
was used for confirmation. Positive antidrug antibody
samples were subsequently tested for the presence of
neutralizing antibodies; a 1% false-positive
neutralizing antibody cut-point was used for
confirmation.
The annualized rate of exacerbations was the
primary efficacy endpoint. An exacerbation was
defined as a worsening of asthma that required
systemic corticosteroids, hospitalization, or anOctober 2019emergency department visit. Systemic corticosteroids
comprised OCS or IV corticosteroids for 3 days or
a single intramuscular corticosteroid dose; for
patients on maintenance systemic corticosteroids, at
least double the existing maintenance dose was
required for 3 days. Secondary efficacy endpoints
included ACQ-5 score and pre-bronchodilator FEV1
over the study period. OCS use was summarized for
those patients who had participated in the SIRIUS
study.
Statistical Analysis
No sample size calculations were required for this
study: this factor was determined by the number of
available and eligible patients who were enrolled in
COSMOS. All analyses were performed by using
data from patients who received at least 1 dose of
open-label mepolizumab within COSMEX.
The proportion of patients reporting AEs was
summarized by using the Medical Dictionary for
Regulatory Activities Primary System Organ Class
(SOC) and preferred term. Exposure-adjusted AE
rates were presented to account for the length of
exposure within COSMEX and to allow for
comparisons versus previous mepolizumab studies.
Annualized rate of asthma exacerbations was
analyzed by using a negative binomial generalized
linear model, with logarithm of time on treatment
included as an offset variable. Exacerbations
separated by < 7 days were treated as a continuation
of the same exacerbation. All endpoints were
summarized by using appropriate descriptive statistics
(mean/geometric mean, median, SD, and range). For
blood eosinophil counts, if a result of zero was
recorded, a small value (ie, one half the minimum
non-zero result) was imputed before log-
transformation. All statistical analyses were
performed by using SAS version 9.4 (SAS Institute,
Inc, Cary, North Carolina).
RESULTS
Patient Population
Description of patient entry into COSMEX from the
MENSA, SIRIUS, and COSMOS studies is shown in
Figure 1. In total, 340 patients were enrolled in
COSMEX, and 339 received treatment with open-
label mepolizumab (1 patient was excluded because
they had not had an exacerbation during MENSA2045
Clinical Therapeuticswhile on placebo, and they therefore failed the
exacerbation history criterion for COSMEX) (see the
Supplemental Material in the online version at
doi:10.1016/j.clinthera.2019.07.007). All patients
previously received mepolizumab 100 mg SC in the
COSMOS study, and the majority (78%) had
previously participated in the MENSA study.
Demographic and baseline characteristics of the study
population are shown in Table II. The median
duration of mepolizumab treatment in the COSMEX
study was 2.2 years (range, 8 weekse3.3 years),
equating to 718 patient-years of exposure (Table II).
The total exposure in the 339 patients studied across
MENSA, SIRIUS, COSMOS, and COSMEX was
1202 patient-years, with a maximum exposure
duration of 4.8 years.
Seventy-five percent of patients had 12 weeks
between the last dose in COSMOS and the first dose
in COSMEX. For those patients with a prolonged
gap in treatment between studies (>12 weeks
between doses), a statistically significant increase in
ACQ-5 score and blood eosinophil levels, and a
clinically important decrease in lung function, were
observed at baseline compared with those who had
12 weeks between doses (Table II). There were no
differences in concomitant medication use between
the continuous and interrupted mepolizumab groups
(Table II); all patients continued to receive
background standard-of-care asthma medications
throughout.
All 339 patients had discontinued by study
conclusion; almost one half (47% [159 of 339])
remained in the study until mepolizumab became
commercially available in their country, and 45%
(153 of 339) of patients discontinued because the
study was closed/terminated in their country. The
most common reasons for withdrawal before
mepolizumab became commercially available or study
closure were withdrawal of consent (4% [15 of 339]),
lost to follow-up (1% [4 of 339]), and AEs (1% [4 of
339]) (see Supplemental Table I in the online version
at doi:10.1016/j.clinthera.2019.07.007). There was a
low dropout rate in the first year, after which the
dropout rate increased as patients left the study due to
the country-specific commercial availability of
mepolizumab as per the protocol-defined stopping
criteria (see the Supplemental Figure 1 in the online
version at doi:10.1016/j.clinthera.2019.07.007).2046Safety
Overall, 315 (93%) patients reported on-treatment
AEs; 51 (15%) experienced an AE that was
considered by the investigator to be treatment
related. Four (1%) patients were withdrawn from the
study due to AEs (patient 1, asthma exacerbation,
anxiety disorder, and neurodermatitis; patient 2,
elevated liver function test result; patient 3,
musculoskeletal pain; and patient 4, severe asthma
exacerbation with fatal multiple organ dysfunction
and systemic inflammatory response) (see the
Supplemental Material in the online version at
doi:10.1016/j.clinthera.2019.07.007). Two patients
(0.6%) were withdrawn due to lack of efficacy (see
Supplemental Table 1 in the online version at doi:10.
1016/j.clinthera.2019.07.007). Eighty-four (25%)
patients experienced SAEs during treatment, of whom
3 (0.9%) experienced an SAE that was considered by
the investigator to be treatment related. The most
common on-treatment SAE was asthma
(exacerbation), which occurred in 34 (10%) patients,
with other SAEs occurring at a lower frequency
(Figure 2). Pneumonia was the only other on-
treatment SAE to occur in >1% of patients,
occurring in 6 (2%) patients. Pneumonia was
confirmed by radiograph, computerized tomography
scan, or sputum culture.
On-treatment AEs of special interest are
summarized in Table III. Two (<1%) patients
experienced investigator-defined systemic reactions,
both of which were considered hypersensitivity
reactions related to mepolizumab. The first patient
reported malaise with headache, and the second
reported dizziness with light-headedness. Both were
nonserious and mild to moderate in intensity,
reportedly have resolved, and did not lead to
mepolizumab discontinuation. No nonallergic
systemic reactions or mepolizumab-related
anaphylaxis were reported. Two patients reported
anaphylaxis considered unrelated to mepolizumab by
the investigator; mepolizumab was continued in both
cases. Injection-site reactions were reported by 14
(4%) of 339 patients. Patients with events potentially
representing opportunistic infections involved Herpes
(n ¼ 8), Candida (n ¼ 3), and pulmonary
tuberculosis (n ¼ 1). Three additional patients also
reported Herpes zoster infections, all of which were
nonserious and resolved with continued mepolizumabVolume 41 Number 10
Table II. Patient demographic characteristics, baseline characteristics, and treatment exposure. Continued and
interrupted groups reflect patients with a treatment interval 12 weeks and >12 weeks, respectively,
between COSMOS (A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects)












Demographic and baseline characteristics*
Female 128 (50) 50 (59) 178 (53)
Age, mean (SD), y 53.4 (13.0) 51.5 (13.2) 52.9 (13.1)
Race, no. (%)
White 205 (81) 79 (93) 284 (84)
Asian 49 (19) 2 (2) 51 (15)
African-American/African heritage 0 (0) 4 (5) 4 (1)
Ethnicity, Hispanic/Latino, no. (%) 6 (2) 12 (14) 18 (5)




















Blood eosinophil count, cells/mL,







Concurrent therapy, no. (%) (COSMEX)
Inhaled corticosteroid 247 (97) 82 (96) 329 (97)
Long-acting beta2- agonist 250 (98) 82 (96) 332 (98)
Short-acting beta2- agonist 213 (84) 67 (79) 280 (83)
Leukotriene receptor antagonist 117 (46) 34 (40) 151 (45)
Long-acting muscarinic antagonist 57 (22) 19 (22) 76 (22)
Xanthine 61 (24) 11 (13) 72 (21)
Interval between COSMOS and COSMEX study dosing
Interval between COSMOS and COSMEX study dosing,
median (range), wk
4.1 (1e12) 27.3 (12e40) 5.0 (1e40)
Interval period between COSMOS and COSMEX
study dosing, no. (%)
4 wk 112 (44) 0 112 (33)
>4e8 wk 106 (42) 0 106 (31)
>8e12 wk 36 (14) 0 36 (11)
>12e16 wk 0 13 (15) 13 (4)
>16e20 wk 0 8 (9) 8 (2)
>20e24 wk 0 11 (13) 11 (3)
>24 wk 0 53 (62) 53 (16)
Mepolizumab exposure (COSMEX)
Time on treatment, median (range), mo e e 26.8 (2e39)
(continued on next page)














Total patient-years exposure e e 718.38
Period of exposure, no. (%)
6 mo e e 333 (98)
12 mo e e 328 (97)
24 mo e e 197 (58)
36 mo e e 31 (9)
Mepolizumab exposure (MENSA, SIRIUS, COSMOS, and COSMEX)
Time on treatment, median (range), mo e e 42.9 (14e57)
Total patient-years exposure e e 1201.93
Period of exposure, no. (%)
12 mo e e 339 (100)
24 mo e e 333 (98)
36 mo e e 262 (77)
48 mo e e 128 (38)
ACQ-5 ¼ Asthma Control Questionnaire-5; FEV1 ¼ forced expiratory volume in 1 s; MENSA ¼ Mepolizumab as Adjunctive
Therapy in Patients with Severe Asthma; SC ¼ subcutaneous; SIRIUS ¼ Steroid Reduction with Mepolizumab Study.
* The demographic and baseline characteristics section presents patients' characteristics when commencing COSMEX
(COSMOS Extension).
y Lower scores reflect greater asthma control.
Clinical Therapeuticstreatment. Malignancies were reported in 8 (2%)
patients: basal cell carcinoma (n ¼ 2), prostate cancer
(n ¼ 2), breast cancer (n ¼ 1), colon adenocarcinoma
(n ¼ 1), colon neoplasm (n ¼ 1), and melanoma
(n ¼ 1). Five investigator-reported nonfatal
cardiovascular events were reviewed by the Clinical
Endpoint Committee; of these, 3 patients had events
adjudicated as cardiovascular (myocardial infarction
in all 3 patients).
Overall, 2 fatalities were reported and adjudicated by
the Clinical Endpoint Committee, one as respiratory
and the other as cardiovascular; neither death was
considered related to mepolizumab by the investigator
(details are given in the Supplemental Material in the
online version at doi:10.1016/j.clinthera.2019.07.007).
In total, 335 patients were tested for the presence of
anti-mepolizumab antibodies after the first
mepolizumab dose within COSMEX; 6 (2%) had
anti-mepolizumab antibodies at least once
postbaseline with no neutralizing antibodies detected.
No relationship between the frequency of AEs or2048hypersensitivity reactions and the presence or absence
of antidrug antibodies was observed.
Efficacy
In total, 215 (63%) of 339 patients experienced 658
on-treatment exacerbations over the on-treatment
period (median duration, 2.2 years; range, 8
weeks−3.3 years). The annualized on-treatment
exacerbation rate (95% CI) was 0.93 (0.81e1.06)
event/year. The annualized rate of on-treatment
exacerbations requiring hospitalization or an
emergency department visit was 0.13 (0.10e0.18)
event/year and 0.07 (0.05e0.10) event/year for those
requiring hospitalization. Those patients with
continuous study participation since MENSA
reported a sustained reduction in exacerbation rate
with prolonged mepolizumab treatment throughout
multiple studies (MENSA, COSMOS, and COSMEX)
(Figure 3).
Patients with a treatment gap >12 weeks between

















































Nasal polyps 4 (1)
RTI 3 (0.9)
Foot fracture 3 (0.9)















Back pain 42 (12)
Hyponatremia
Figure 2. Summary of (A) on-treatment adverse event (AEs) occurring in >10% of patients and (B) on-
treatment serious AEs occurring in >1 patient. GERD ¼ gastroesophageal reflux disease;
RTI ¼ respiratory tract infection.
S. Khurana et al.their asthma; however, after re-starting mepolizumab,
patients experienced improvements in asthma control
as measured according to the ACQ-5 score
(Figure 4A). There was also a slight improvement in
lung function as measured by using FEV1 (Figure 4B)
and a marked reduction in blood eosinophil levels
after re-introduction of mepolizumab (Figure 4C).
Patients with continuous mepolizumab treatment
presented limited changes in efficacy parameters,
reflecting a continuation of the benefits observed withOctober 2019mepolizumab treatment in previous studies. Those
patients who had continuous study participation
since the corticosteroid-sparing SIRIUS study (and
therefore required OCS before randomization in
SIRIUS) exhibited a sustained reduction in daily OCS
usage with prolonged mepolizumab treatment
throughout multiple studies (SIRIUS, COSMOS, and
COSMEX) (Figure 5; see Supplemental Table II in
the online version at doi:10.1016/j.clinthera.2019.07.
007). In addition, 17 (45%) of 38 patients with2049
Table III. Summary of on-treatment adverse events of special interest. Values are given as no. (%).
Adverse Event Mepolizumab 100 mg SC (N ¼ 339)
Systemic reactions* 2 (0.6)
Allergic/hypersensitivity reactions 2 (0.6)
Nonallergic reactions 0
Anaphylaxisy 0
Local injection-site reactions* 14 (4)
All infectionsz 282 (83)
Serious infections 20 (6)
Opportunistic infectionsx 15 (4)
Neoplasmsz 20 (6)
Malignanciesǁ 8 (2)
Cardiac disordersz 15 (4)
Serious cardiac disorders 6 (2)
Serious CVT events¶ 7 (2)
Serious ischemic events# 3 (0.9)
CVT ¼ cardiac, vascular and thromboembolic; SC ¼ subcutaneous.
* As identified by the investigator in electronic case report form designed for collecting data on systemic reactions or local
injection-site reactions.
yConsidered by the investigator to represent a systemic reaction meeting Sampson's criteria (Sampson HA, Munoz-Furlong A,
Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary reportdSecond National
Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol.
2006;117:391e397) for anaphylaxis.
zAll infections included all events in Infections and infestations System Organ Class (SOC); neoplasms include all events in
Neoplasms benign malignant and unspecified (including cysts and polyps) SOC; cardiac disorders includes all events in
Cardiac disorders SOC.
x Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as opportunistic
infections in the setting of biologic therapy (Winthrop KL, Novosad SA, Baddley JW, et al. Opportunistic infections and biologic
therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials
and postmarketing surveillance. Ann Rheum Dis. 2015;74:2107e211).
ǁAll neoplasms were identified from Neoplasms benign, malignant and unspecified (including cysts and polyps) SOC and
standard Medical Dictionary for Regulatory Activities (MedDRA) queries.
¶All serious CVT events were identified from Cardiac Disorders SOC, Vascular Disorders SOC, and standard MedDRA queries.
# Subset of serious CVT events was identified through standard MedDRA queries.
Clinical Therapeutics128 weeks of continuous reporting across SIRIUS,
COSMOS, and COSMEX no longer required OCS
treatment between weeks 124 and 128, and 7 (58%)
of 12 patients with data up to 232 weeks no longer
required OCS between weeks 228 and 232 (see
Supplemental Table III in the online version at
doi:10.1016/j.clinthera.2019.07.007).
DISCUSSION
In selected patients with the most severe forms of
severe eosinophilic asthma who had previously
shown clinical benefit with mepolizumab, long-term2050treatment with mepolizumab throughout COSMEX
and previous leadein studies was well tolerated and
provided sustained and consistent reductions in
exacerbation rate, with sustained improvements in
ACQ-5 score and FEV1 over a period of up to 4.5
years. Furthermore, the reduction in OCS dose
initially achieved during SIRIUS was also sustained,
with additional patients no longer requiring OCS
treatment following continued mepolizumab
treatment across the SIRIUS, COSMOS, and
COSMEX studies. This study extends our knowledge






































Figure 3. Exacerbation rate per year throughout the MENSA (Mepolizumab as Adjunctive Therapy in Patients
with Severe Asthma), COSMOS (A Study to Determine Long-term Safety of Mepolizumab in Asth-
matic Subjects), and COSMEX (COSMOS Extension) studies in patients with 188 weeks of
continuous enrollment. In total, 95 patients with 188 weeks of continuous reporting across
MENSA, COSMOS, and COSMEX with 12 weeks between the last dose in COSMOS and first dose
in COSMEX are summarized (MENSA, placebo, n ¼ 24; mepolizumab, n ¼ 71). The mepolizumab
group in MENSA contains patients on both 100 mg SC and 75 mg IV doses. Analyses include clinically
significant exacerbations from MENSA and all exacerbations from COSMOS and COSMEX. *Pre-
treatment refers to the 12 months before enrollment in MENSA.
S. Khurana et al.in a population of patients with the most severe forms
of eosinophilic asthma.
The type and frequency of the AEs, including fatal
events and events of special interest, reported in this
study were broadly consistent with those reported in
other mepolizumab clinical studies,11e15 and no new
safety concerns were identified. Immunogenicity
incidence was low and consistent with previous
mepolizumab studies in severe eosinophilic asthma,
and no patients tested positive for neutralizing
antibodies 11e15.
The primary efficacy endpoint for this study was the
annualized exacerbation rate, which was estimated at
0.93 event/year, consistent with findings from the
COSMOS and COLUMBA (Open-label Long Term
Extension Safety Study of Mepolizumab in Asthmatic
Subjects; MEA115666/NCT01691859) mepolizumab
studies in which rates of 0.93 and 0.68 event/year,
respectively, were reported.13,16 In addition, thoseOctober 2019patients with continuous study participation since
MENSA reported a sustained reduction in
exacerbation rate with mepolizumab. Patients with
188 weeks of continuous enrollment across MENSA,
COSMOS, and COSMEX presented an annualized
exacerbation rate of ~5 events/year in the 12 months
before MENSA, which was reduced by mepolizumab
to ~1 event/year across studies. There were limited
changes in efficacy parameters (ACQ-5 and FEV1) in
COSMEX, demonstrating the persistence of clinical
benefit in responsive patients treated continuously with
mepolizumab with no sign of loss of efficacy. The
withdrawal rate due to a lack of efficacy was very low,
further supporting the durability of mepolizumab.
Furthermore, we observed that long-term
mepolizumab treatment provided a sustained OCS
reduction and no evidence of tolerance to
mepolizumab after long-term administration, with
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Figure 4. On-treatment absolute values in (A) Asthma Control Questionnaire-5 (ACQ-5) score, (B) pre-
bronchodilator forced expiratory volume in 1 s (FEV1), and (C) peripheral blood eosinophil count
in patients receiving continuous compared with interrupted mepolizumab treatment in COSMEX
(COSMOS Extension). Values have not been displayed when n ¼ 1. Error bars represent 95% CIs.
Continued and interrupted groups reflect patients with a treatment interval of 12 weeks and >12
weeks, respectively, between COSMOS (A Study to Determine Long-term Safety of Mepolizumab in
Asthmatic Subjects) and COSMEX. SC ¼ subcutaneous.
S. Khurana et al.Although most patients enrolled in COSMEX had
minimal gaps between successive clinical studies, a
small proportion experienced a prolonged interruption
in mepolizumab treatment (>12 weeks between
COSMOS and COSMEX doses). These patients
showed a worsening in lung function (FEV1) and
asthma control (ACQ-5 score) and an increase in
blood eosinophil count at baseline compared with
patients who had maintained continuous therapy.



























































































Figure 5. Oral corticosteroid (OCS) use throughout the S
COSMOS (A Study to Determine Long-term
COSMEX (COSMOS Extension) studies in pat
total, 38 patients with 128 weeks of continuo
with 12 weeks between the last dose in CO
(SIRIUS, placebo, n ¼ 18; mepolizumab, n ¼
equivalent dose.
October 2019COLUMBA safety study, in which the cessation of
mepolizumab led to increases in blood eosinophil
levels and frequency of exacerbations approaching
pretreatment levels.16 In severe eosinophilic asthma,
frequent exacerbations have been associated with a
loss in lung function, compared with those with no or
infrequent exacerbations.17e19 In addition, another
study also showed that cessation of mepolizumab
resulted in significant between-visit increases in blood
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IRIUS (Steroid Reduction with Mepolizumab Study),
Safety of Mepolizumab in Asthmatic Subjects), and
ients with 128 weeks of continuous enrollment. In
us reporting across SIRIUS, COSMOS, and COSMEX
SMOS and first dose in COSMEX are summarized
20). Data are summarized in terms of prednisone
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Clinical Therapeuticsand a loss of asthma control (according to the Juniper
Asthma Control Questionnaire) over the 12-month
follow-up period.20 This scenario indicates that short-
term use of mepolizumab (up to ~18 months) seemed
to have no long-term disease-modifying effect in adult
patients with severe asthma, and thus continuous
treatment is necessary to obtain a sustained clinical
benefit. It should be noted that despite these findings,
and as observed in the COLUMBA study,16 the
interruption in treatment between COSMOS and
COSMEX had no subsequent negative impact on the
safety and efficacy of mepolizumab after treatment
was resumed. Although a worsening in the interrupted
group and further improvements in the continuous
group, respectively, were observed in FEV1 and ACQ-
5 scores toward the end of the study, these findings
were most likely a reflection of the low patient
numbers at later time points.
The current study has several limitations. Regarding
the study design, the lack of a placebo-controlled arm
means it is difficult to make robust clinical
interpretations regarding any treatment-related
outcomes. Patient recruitment to this extension study
was also biased toward those who responded to
mepolizumab, and those without AEs leading to
discontinuation from the previous studies, which may
have positively affected long-term mepolizumab
safety and efficacy. Approximately 370 of the 651
patients from COSMOS were eligible for continued
mepolizumab treatment within COSMEX when
assessed against the life-threatening/seriously
debilitating and clinical benefit eligibility criteria,
with the majority (92%) of eligible patients entering
this extension study. Subsequently, the percentage of
patients enrolled into COSMEX from the COSMOS
trial was ~50%, and into COSMOS from the
MENSA and SIRIUS trials was ~90%. These
proportions are noteworthy because, owing to the
nature of the studies, each subsequent study favored
patients who responded to mepolizumab; however,
these criteria for continued treatment are consistent
with those of clinical practice. The use of
background asthma therapies was also not
systematically checked during this study; instead, it
was at the investigator's discretion whether to reduce
or change background therapies. This approach may
have influenced the results to some extent, and in
particular, any changes in bronchodilator therapy
may have affected the results on lung function.2054Owing to the attrition of patients during this study,
later-stage efficacy endpoints should also be
interpreted with caution because the results are based
on fewer patients compared with the first 2 years of
the COSMEX study.
CONCLUSIONS
The long-term safety profile of mepolizumab 100 mg
SC every 4 weeks in patients with the most severe
forms of severe eosinophilic asthma and responsive to
mepolizumab was similar to that seen in previous
mepolizumab studies in patients with severe
eosinophilic asthma, with no new safety concerns
identified. In this selected group of patients,
improvements in asthma control and reductions in
blood eosinophil levels were maintained, and a
strong and consistent reduction in exacerbations and
chronic OCS use was sustained over time with
prolonged mepolizumab treatment, whereas cessation
of mepolizumab treatment led to loss of asthma
control. Together, these findings confirm the stable
and persistent response to mepolizumab observed in
previous clinical trials and support the use of
mepolizumab as a long-term treatment choice for
patients with severe eosinophilic asthma.
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S. Khurana et al.APPENDIX A. SUPPLEMENTARY MATERIAL
The following are the supplementary data to this
article:
Study Locations
The study was conducted in the following countries:
Argentina, Australia, Belgium, Canada, Chile, Czechia,
France, Germany, Italy, Japan, South Korea, the
Netherlands, Poland, the Russian Federation, Spain,
Ukraine, UK and USA.
Protocol-defined Discontinuation Criteria
Each of the following constituted a protocol-defined
discontinuation criterion: mepolizumab became
commercially available in the relevant participating
country; the sponsor discontinued the study in the
relevant participating country; the patient was
withdrawn by their physician; the patient withdrew
consent; or the benefit/risk profile for the patient was
no longer positive in the opinion of the investigator
(supplementary Table I).Protocol-defined Clinical Benefit
The protocol-defined clinical benefit inclusion
criteria were dependent on the patient's previousSupplementary Figure 1. Time to study cessation in COSM
as mepolizumab became comm
country. SC ¼ subcutaneous.
October 2019study enrollment and the randomized treatment that
they were assigned to within MENSA/SIRIUS.
 Patients from MENSA were required to have:
o A reduction in exacerbation frequency by  50%
compared with the 12 months prior to screening
for MENSA, during MENSA for those patients
randomized to mepolizumab, and during the
first 8 months of COSMOS for those
randomized to placebo.
o Investigator-confirmed improvement during
MENSA for those randomized to mepolizumab,
and during COSMOS for those randomized to
placebo.
 Patients from SIRIUS were required to have:
o A reduction in oral corticosteroids (OCS) dose
by  50% compared with the patient's
optimized OCS dose at randomization in
SIRIUS, during SIRIUS for those randomised to
mepolizumab, and during the first 6 months of
COSMOS for those randomised to placebo.
o Investigator-confirmed improvement during
SIRIUS for those randomised to mepolizumab,
and during COSMOS for those randomised to
placebo.EX. Study closure was conducted in a staged manner
ercially available for prescription in each participating
2056.e1






Completion status, n (%)
Discontinued 339 (100)
Completed 0 (0)




Study closed/terminated 153 (45)
Withdrawal of consent 15 (4)
Lost to follow-up 4 (1)
Adverse eventb 3 (0.9)
Lack of efficacy 2 (0.6)
Protocol deviation 2 (0.6)
Pregnancy 1 (0.3)





aOne patient withdrew from the study because
mepolizumab became commercially available and died
after receiving a single commercially available dose.
b Elevated liver chemistry results also considered an
adverse event. SC ¼ subcutaneous.
Supplementary Table II. Oral corticosteroid use
throughout the SIRIUS,
COSMOS and COS-
MEX studies in patients
with 232 weeks of
continuous enrollment.
Patients with data up to






Optimized dose 10.0 12.5
Weeks 0e4 10.0 12.5
Weeks 4e8 6.7 10.0
Weeks 8e12 10.0 5.0
Weeks 12e16 9.0 5.0
Weeks 16e20 5.0 2.5
Weeks 20e24 2.5 2.2
COSMOS
Weeks 24e28 e 1.7
Weeks 28e32 e 1.6
Weeks 32e36 e 1.4
Weeks 36e40 e 2.6
Weeks 40e44 e 2.9
Weeks 44e48 e 1.9
Weeks 48e52 e 1.9
Weeks 52e56 e 1.9
Weeks 56e60 e 3.0
Weeks 60e64 e 1.9
Weeks 64e68 e 3.8
Weeks 68e72 e 3.8
Weeks 72e76 e 1.9
COSMEX
Weeks 76e80 e 1.3
Weeks 80e84 e 1.3
Weeks 84e88 e 1.3
Weeks 88e92 e 1.5
Weeks 92e96 e 1.3
Weeks 96e100 e 1.3
Weeks 100e104 e 1.6
Weeks 104e108 e 2.5
Weeks 108e112 e 1.9
Weeks 112e116 e 1.9
Weeks 116e120 e 0.6
Weeks 120e124 e 0.6
Weeks 124e128 e 1.3
Clinical TherapeuticsExclusion Criteria
Exclusion criteria included: a clinically significant
change in health status during the COSMOS study,
according to the investigator; pregnancy or
breastfeeding; current smokers; or a clinically
significant electrocardiogram abnormality determined
by the investigator. Patients who received placebo in
MENSA and had no exacerbations during that study
and patients who received placebo in SIRIUS and
were able to discontinue OCS therapy by the end of
the study were not deemed severe enough to continue
to receive mepolizumab in the COSMEX study.
 Screen failure: 1 patient was excluded due to a
screening failure; they did not meet inclusion/
exclusion for exacerbation history (i.e. received2056.e2 Volume 41 Number 10
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Patients with data up to





Weeks 128e132 e 0.6
Weeks 132e136 e 0.6
Weeks 136e140 e 1.6
Weeks 140e144 e 1.4
Weeks 144e148 e 2.5
Weeks 148e152 e 1.9
Weeks 152e156 e 1.9
Weeks 156e160 e 0.0
Weeks 160e164 e 0.0
Weeks 164e168 e 1.0
Weeks 168e172 e 0.6
Weeks 172e176 e 0.6
Weeks 176e180 e 0.0
Weeks 180e184 e 0.0
Weeks 184e188 e 0.0
Weeks 188e192 e 0.0
Weeks 192e196 e 1.3
Weeks 196e200 e 2.1
Weeks 200e204 e 1.3
Weeks 204e208 e 0.0
Weeks 208e212 e 0.0
Weeks 212e216 e 0.0
Weeks 216e220 e 0.0
Weeks 220e224 e 0.0
Weeks 224e228 e 0.0
Weeks 228e232 e 0.0
a In total, 14 patients had 232 weeks of continuous
reporting across SIRIUS, COSMOS, and COSMEX with
12 weeks between the last dose in COSMOS and the
first dose in COSMEX. Of these 14 patients, 7 and 7
received placebo and mepolizumab, respectively, during
the double-blinded SIRIUS study and then received
mepolizumab during the open-label COSMOS and
COSMEX studies. Data are summarized in terms of
prednisone equivalent dose. OCS ¼ oral corticosteroid;
SC ¼ subcutaneous.







in patients with 232
weeks of continuous
enrollment.
Patients with data up to
232 weeks (n ¼ 14a)
n/N (%) with 100%




Optimized dose 0 0
Weeks 0e4 0 0
Weeks 4e8 0 0
Weeks 8e12 0 0
Weeks 12e16 0 0
Weeks 16e20 0 1/7 (14%)
Weeks 20e24 2/7 (29%) 1/7 (14%)
COSMOS
Weeks 24e28 e 2/13 (15%)
Weeks 28e32 e 2/13 (15%)
Weeks 32e36 e 2/14 (14%)
Weeks 36e40 e 3/14 (21%)
Weeks 40e44 e 4/14 (29%)
Weeks 44e48 e 4/14 (29%)
Weeks 48e52 e 4/14 (29%)
Weeks 52e56 e 4/14 (29%)
Weeks 56e60 e 4/14 (29%)
Weeks 60e64 e 4/14 (29%)
Weeks 64e68 e 3/14 (21%)
Weeks 68e72 e 3/14 (21%)
Weeks 72e76 e 4/14 (29%)
COSMEX
Weeks 76e80 e 3/13 (23%)
Weeks 80e84 e 5/13 (38%)
Weeks 84e88 e 6/14 (43%)
Weeks 88e92 e 5/14 (36%)
Weeks 92e96 e 5/14 (36%)
Weeks 96e100 e 5/14 (36%)
Weeks 100e104 e 5/14 (36%)
Weeks 104e108 e 3/13 (23%)
(continued on next page)
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Supplementary Table III. (Continued)
Patients with data up to
232 weeks (n ¼ 14a)
n/N (%) with 100%
reduction in OCS dose
Placebo Mepolizumab
100 mg SC
Weeks 108e112 e 4/13 (31%)
Weeks 112e116 e 4/13 (31%)
Weeks 116e120 e 7/14 (50%)
Weeks 120e124 e 7/14 (50%)
Weeks 124e128 e 6/14 (43%)
Weeks 128e132 e 7/14 (50%)
Weeks 132e136 e 7/14 (50%)
Weeks 136e140 e 5/14 (36%)
Weeks 140e144 e 3/12 (25%)
Weeks 144e148 e 3/12 (25%)
Weeks 148e152 e 5/14 (36%)
Weeks 152e156 e 5/14 (36%)
Weeks 156e160 e 8/14 (57%)
Weeks 160e164 e 8/14 (57%)
Weeks 164e168 e 6/14 (43%)
Weeks 168e172 e 7/14 (50%)
Weeks 172e176 e 7/14 (50%)
Weeks 176e180 e 9/14 (64%)
Weeks 180e184 e 8/13 (62%)
Weeks 184e188 e 8/13 (62%)
Weeks 188e192 e 8/14 (57%)
Weeks 192e196 e 6/13 (46%)
Weeks 196e200 e 4/14 (29%)
Weeks 200e204 e 7/14 (50%)
Weeks 204e208 e 8/14 (57%)
Weeks 208e212 e 9/14 (64%)
Weeks 212e216 e 9/14 (64%)
Weeks 216e220 e 8/13 (62%)
Weeks 220e224 e 8/13 (62%)
Weeks 224e228 e 7/12 (58%)
Weeks 228e232 e 7/12 (58%)
a In total, 14 patients had 232 weeks of continuous
reporting across SIRIUS, COSMOS and COSMEX with
12 weeks between the last dose in COSMOS and the
first dose in COSMEX. Of these 14 patients, 7 and 7
received placebo and mepolizumab, respectively, during
the double-blinded SIRIUS study and then received
mepolizumab during the open-label COSMOS and
COSMEX studies. Data are summarized in terms of
prednisone equivalent dose. OCS ¼ oral corticosteroid;
SC ¼ subcutaneous.
Clinical Therapeutics
2056.e4placebo in MENSA but had no exacerbations
during the study).
Adverse Events (AEs) of Special Interest
Within the mepolizumab clinical development
program, AEs of special interest include: systemic
(allergic/hypersensitivity and non-allergic) reactions,
local injection-site reactions, infections (including
serious and opportunistic infections), malignancies,
serious cardiac, vascular and thromboembolic events,
and serious ischemic events.
Cardiovascular events adjudicated by a Clinical
Endpoint Committee
The following cardiovascular events were sent for
adjudication by a Clinical Endpoint Committee:
cerebrovascular events/stroke or transient ischemic
attack, congestive heart failure, deep venous
thrombosis, myocardial infarction/unstable angina,
and peripheral arterial thrombosis embolism.
AEs Leading To Patient Withdrawal From Trial
Further details of the four patients who withdrew
from COSMEX due to AEs are provided below:
 A 25-year-old male was withdrawn due to AEs of
asthma exacerbation, anxiety disorder and
neurodermatitis, each noted as severe.
 A 53-year-old male was withdrawn due to an AE of
elevated liver function test, noted as severe. This was
noted by the investigator as being related to health
supplements (silymarin and saw palmetto).
 A 53-year-old female was withdrawn due to an AE
of musculoskeletal pain, noted as severe, and
considered related to treatment by the reporting
investigator.
 A 65-year-old female experienced an on-treatment
serious AE of severe asthma exacerbation and was
withdrawn from the study; this patient subsequently
developed multiple organ dysfunction and systemic
inflammatory response syndrome post-treatment,
both of which were fatal, as described below.Fatalities In COSMEX
Further details of the two deaths occurring in
COSMEX, both of which were not considered related
to study treatment by the investigator, are provided
below:Volume 41 Number 10
S. Khurana et al. A 65-year-old female died of severe asthma
exacerbation, leading to multiple organ
dysfunction and systemic inflammatory response
syndrome.
 A 72-year-old female with a history of aortic valve
stenosis died of brain hypoxia, cardio-respiratory
arrest, and cerebrovascular disorder. Her death
occurred after she withdrew from the study,
because of mepolizumab becoming commercially
available, and after taking the first dose of
commercially available mepolizumab.October 2019 2056.e5
